CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)

被引：0
|
作者：
Popat, Rakesh [1 ]
Wilson, William [2 ]
Camilleri, Marquita [2 ,3 ]
De Tute, Ruth
Pang, Gavin [2 ]
Jenner, Richard [2 ]
Dadaga, Tushhar [2 ]
Kamora, Sumaiya [2 ]
Streetly, Matthew [4 ]
Ramasamy, Karthik [5 ]
Phillips, Elizabeth [6 ]
Chapman, Mike [7 ]
Bygrave, Ceri [8 ]
Cavenagh, James [9 ]
Sive, Jonathan [2 ,10 ]
Benjamin, Reuben
Eccersley, Lydia [9 ]
Hassan, Sandra [11 ]
Willis, Fenella [12 ]
Clifton-Hadley, Laura [13 ]
Owen, Roger [14 ]
Yong, Kwee [2 ]
机构：
[1] Univ Coll London Hosp NHS Fdn Trust, London, England
[2] UCL, Canc Res UK & UCL Canc Trials Ctr, London, England
[3] St James Hosp Leeds, HMDS, Leeds, W Yorkshire, England
[4] Guys & St Thomas NHS Trust, Leeds, W Yorkshire, England
[5] Univ Oxford, Hosp NHS Trust, Oxford, England
[6] Christie NHS Fdn Trust, Manchester, Lancs, England
[7] Cambridge Inst Med Res, Cambridge, England
[8] Univ Hosp Wales, London, England
[9] Barts Hlth NHS Trust, London, England
[10] Kings Coll Hosp London, London, England
[11] Queens Hosp, London, England
[12] St Georges NHS Trust, London, England
[13] UCL, Canc Res UK & UCL Canc Trials Ctr, London, England
[14] St James Inst Oncol, London, England
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OAB-003
引用
收藏
页码：S2 / S3
页数：2
相关论文
共 50 条
  • [21] A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard- Risk Patients
    Gay, Francesca Maria
    Scalabrini, Delia Rota
    Belotti, Angelo
    Galli, Monica
    Zamagni, Elena
    Offidani, Massimo
    Oliva, Stefania
    Montefusco, Vittorio
    Zambello, Renato
    Ledda, Antonio
    Grasso, Mariella
    Aquino, Sara
    Esma, Fabrizio
    Tosi, Patrizia
    Pisani, Francesco
    Annibali, Ombretta
    Liberati, Anna Marina
    Baraldi, Anna
    Galieni, Piero
    Specchia, Giorgina
    Pescosta, Norbert
    Mancuso, Katia
    Paris, Laura
    Ribolla, Rossella
    Coha, Valentina
    Palumbo, Antonio
    Musto, Pellegrino
    Cavo, Michele
    Boccadoro, Mario
    BLOOD, 2017, 130
  • [22] Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate
    Sonneveld, Pieter
    Asselbergs, Emilie
    Zweegman, Sonja
    Van der Holt, Bronno
    Kersten, Marie Jose
    Vellenga, Edo
    van Marwijk-Kooy, Marinus
    de Weerdt, Okke
    Lonergan, Sarah
    Lokhorst, Henk
    BLOOD, 2012, 120 (21)
  • [23] Carfilzomib (CFZ, Kyprolis®), Lenalidomide (LEN, Revlimide®), and Dexamethasone (DEX) (KRd) Combined with Autologous Stem Cell Transplant (ASCT) Shows Improved Efficacy Compared with Krd without ASCT in Newly Diagnosed Multiple Myeloma (NDMM)
    Zimmerman, Todd M.
    Griffith, Kent
    Jasielec, Jagoda K.
    Rosenbaum, Cara A.
    Berdeja, Jesus G.
    Vij, Ravi
    Raje, Noopur
    Reece, Donna E.
    Vesole, David H.
    Jagannath, Sundar
    Kaminski, Mark
    Cole, Craig
    Nam, Jennifer
    Stephens, Leonor A.
    Rosebeck, Shaun
    Gurbuxani, Sandeep
    Dytfeld, Dominik
    Jakubowiak, Andrzej J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S40 - S40
  • [24] Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
    Gay, Francesca
    Musto, Pellegrino
    Rota-Scalabrini, Delia
    Bertamini, Luca
    Belotti, Angelo
    Galli, Monica
    Offidani, Massimo
    Zamagni, Elena
    Ledda, Antonio
    Grasso, Mariella
    Ballanti, Stelvio
    Spadano, Antonio
    Cea, Michele
    Patriarca, Francesca
    D'Agostino, Mattia
    Capra, Andrea
    Giuliani, Nicola
    de Fabritiis, Paolo
    Aquino, Sara
    Palmas, Angelo
    Gamberi, Barbara
    Zambello, Renato
    Petrucci, Maria Teresa
    Corradini, Paolo
    Cavo, Michele
    Boccadoro, Mario
    LANCET ONCOLOGY, 2021, 22 (12): : 1705 - 1720
  • [25] Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
    Sonneveld, Pieter
    Asselbergs, Emilie
    Zweegman, Sonja
    van der Holt, Bronno
    Kersten, Marie Jose
    Vellenga, Edo
    van Marwijk-Kooy, Marinus
    Broyl, Annemiek
    de Weerdt, Okke
    Lonergan, Sarah
    Palumbo, Antonio
    Lokhorstl, Henk
    BLOOD, 2015, 125 (03) : 449 - 456
  • [26] Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
    Bringhen, S.
    D'Agostino, M.
    De Paoli, L.
    Montefusco, V.
    Liberati, A. M.
    Galieni, P.
    Grammatico, S.
    Muccio, V. E.
    Esma, F.
    De Angelis, C.
    Musto, P.
    Ballanti, S.
    Offidani, M.
    Petrucci, M. T.
    Gaidano, G.
    Corradini, P.
    Palumbo, A.
    Sonneveld, P.
    Boccadoro, M.
    LEUKEMIA, 2018, 32 (04) : 979 - 985
  • [27] Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
    S Bringhen
    M D'Agostino
    L De Paoli
    V Montefusco
    A M Liberati
    P Galieni
    S Grammatico
    V E Muccio
    F Esma
    C De Angelis
    P Musto
    S Ballanti
    M Offidani
    M T Petrucci
    G Gaidano
    P Corradini
    A Palumbo
    P Sonneveld
    M Boccadoro
    Leukemia, 2018, 32 : 979 - 985
  • [28] Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study
    Yong, Kwee
    Popat, Rakesh
    Wilson, William
    Pang, Gavin
    Jenner, Richard
    De Tute, Ruth M.
    Ramasamy, Karthik
    Streetly, Matthew
    Cavenagh, Jamie
    Sive, Jonathan
    Chapman, Michael
    Bygrave, Ceri
    Phillips, Beth
    Chavda, Selina J.
    Virchis, Andres E.
    Benjamin, Reuben
    Arnott, Sarah
    Willis, Fenella
    Hassan, Sandra
    Moore, Sally
    Clifton-Hadley, Laura
    Owen, Roger G.
    BLOOD, 2019, 134
  • [29] Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).
    Zimmerman, Todd M.
    Griffith, Kent A.
    Jasielec, Jagoda
    Rosenbaum, Cara Ann
    McDonnell, Kathryn
    Waite-Marin, Jessica
    Berdeja, Jesus G.
    Raje, Noopur S.
    Reece, Donna Ellen
    Vij, Ravi
    Alonge, Mattina
    Rosebeck, Shaun
    Gurbuxani, Sandeep
    Faham, Malek
    Kong, Katherine A.
    Levy, Joan
    Jakubowiak, Andrzej J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Geriatric assessment (GA) and eligibility for autologous stem cell transplant (ASCT) in older adults with newly diagnosed multiple myeloma (MM).
    Wildes, Tanya Marya
    Tuchman, Sascha Alexander
    Depp, Brittany
    Chen, Ling
    Stockerl-Goldstein, Keith
    Vij, Ravi
    Colditz, Graham A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345